“NMOSD Market” report has been added to DelveInsight
NMOSD Overview
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).
NMOSD Market
DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request free sample copy- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
NMOSD Market: Regions Covered
NMOSD Market: Key Players
NMOSD Market: Drugs
NMOSD Market: Symptoms
The characteristic symptoms of NMOSD are either optic neuritis or myelitis; either may occur as the first symptom. Optic neuritis is inflammation, of the optic nerve (optic neuritis) leading to pain inside the eye which rapidly is followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). NMOSD may or may not be preceded by a prodromal upper respiratory infection.
NMOSD Market: Treatment
For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not respond to intravenous corticosteroids. For long-term suppression of the disease, a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of NMOSD and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits.
NMOSD Market: Disease
Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which is present in 50% of cases. NMOSD is regarded as an autoimmune disease though the exact cause for the autoimmunity is unknown.
NMOSD Market: Diagnosis
The uncommon disorder Neuromyelitis Optica Spectrum Disorder (NMOSD) may be difficult to interpret because of the evolving nature of diagnostic criteria, differences in the definition and accuracy of NMOSD diagnosis, the completeness of case ascertainment, and variability in assays for the disease‐specific biomarker aquaporin‐4 (AQP4)‐IgG.
NMOSD Market: Insights
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations.
Table of content
1. Key Insights
2. Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)
3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder (NMOSD)
4. Neuromyelitis Optica Spectrum Disorder (NMOSD): Market Overview at a Glance
5. Neuromyelitis Optica Spectrum Disorder (NMOSD): Disease Background and Overview
6. Patient Journey
7. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Neuromyelitis Optica Spectrum Disorder (NMOSD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
What are the NMOSD Market Report Highlights?
Why should you buy this report?
Related Reports
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Shruti Thakur
[email protected]
+91-9650213330
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/